RE:ReplyThanks for sharing. One additional thing I like about this management team is their openness to "learning from their experiences". I am sure Casey is aware shareholders aren't exactly pleased over the past two quarters with the misses. Time will tell, but I am expecting the future quarters to show an improvement in EBiTDA percentage of revenue and management has guided accordingly (as opposed to the prior guidance on EBITDA during the aggressive growth phase). My sense is the market has placed VieMed on a "show me first" category for now.